3683. Deputy Pádraig Rice asked the Minister for Health the status of a drug reimbursement application (details supplied); the timeline being worked towards for a decision; and if she will make a statement on the matter. [57384/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
3722. Deputy Paula Butterly asked the Minister for Health to respond to correspondence received (details supplied) in relation to EU proposals regarding vitamin and mineral supplements; and if she will make a statement on the matter. [57469/26]
3872. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 290 of 27 May 2026, to provide an update on the development of a sandboxed early access programme for rare diseases; if there has been any progress or developments since May; the timeline she is working towards; and if she will make a statement on the matter. [58074/26]
4069. Deputy Rory Hearne asked the Minister for Health to outline the progress her Department has made in reducing the turnaround for reimbursement decisions for orphan drugs; and if she will make a statement on the matter. [59085/26]
4070. Deputy Rory Hearne asked the Minister for Health to provide an update on development of a pathway to timely orphan drug approval; and if she will make a statement on the matter. [59086/26]
4071. Deputy Rory Hearne asked the Minister for Health the steps being taken by her Department to make belzutifan available to patients with von Hippel-Lindau disease; and if she will make a statement on the matter. [59087/26]
4094. Deputy Carol Nolan asked the Minister for Health to provide an update on the status of the HSE assessment of the application for pricing and reimbursement of belzutifan (welireg) (details supplied); to outline the current stage of the application within the HSE's formal assessment and approval processes, including the engagement that has taken place with the applicant; to provide an indicative timeline for comp…
565. Deputy Jennifer Whitmore asked the Minister for Health if there are pathways for women using trial drugs to treat adenomyosis to have their costs fully or partially covered by the State; and if she will make a statement on the matter. [54676/26]
368. Deputy Pádraig O'Sullivan asked the Minister for Health the steps being taken to address the shortage of bumetanide, which has been in short supply since early May 2026 with an expected return date of the end of the year; the interim arrangements in place to protect patients with heart failure who depend on this medicine; and if she will make a statement on the matter. [53753/26]
369. Deputy Pádraig O'Sullivan asked the Minister for Health whether she will bring forward legislative proposals to permit therapeutic substitution by pharmacists during medicine shortages; and if she will make a statement on the matter. [53754/26]
381. Deputy Niamh Smyth asked the Minister for Health if she will provide an update on the HSE's consideration of Skyclarys for the treatment of Friedreich's ataxia; the reason the drug was not included on the agenda of the HSE Drugs Group meeting of 14 July 2026; if she will confirm when a decision is expected; and if she will make a statement on the matter. [53801/26]
400. Deputy Colm Burke asked the Minister for Health to confirm whether nirsevimab, the RSV vaccine, will be made available by the HSE for newborn babies from September 2026; and if she will make a statement on the matter. [53924/26]
699. Deputy Eoin Ó Broin asked the Minister for Health if she will confirm that Skyclarys will be on the agenda for the upcoming HSE Drugs Group meeting in July; and if she will make a statement on the matter. [52634/26]
748. Deputy Claire Kerrane asked the Minister for Health the reason a drug (details supplied) is not accessible in Ireland to cancer patients despite approval by the European Medicines Agency and its accessibility in many other parts of the EU and in the North of Ireland, if she will examine this and make the drug available for cancer patients where their oncology team has recommended it; and if she will make a state…
749. Deputy Charles Ward asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, the reason this data was not provided; when this data will be provided; and the most common reasons recorded for claim adjustment in each year from 2020 to date (details supplied) [52892/26]
750. Deputy Colm Burke asked the Minister for Health her views on extending publicly funded access to continuous glucose monitoring to all women with type 2 diabetes during pregnancy; and if she will make a statement on the matter. [52893/26]
751. Deputy Colm Burke asked the Minister for Health the number of people with a clinical diagnosis of type 1 diabetes who are currently ineligible for publicly funded continuous glucose monitoring access; and if she will make a statement on the matter. [52894/26]
752. Deputy Colm Burke asked the Minister for Health if she will consider widening access to continuous glucose monitoring (CGM) for women with type 2 diabetes during pregnancy (details supplied); and if she will make a statement on the matter. [52895/26]
753. Deputy Colm Burke asked the Minister for Health if the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will encompass a consideration of ensuring that all patients with type one diabetes have access to CGM; and if she will make a statement on the matter. [52898/26]
754. Deputy Colm Burke asked the Minister for Health whether the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will lead to a HTA of CGM sensors for patients with type 2 diabetes; and if she will make a statement on the matter. [52899/26]
755. Deputy Barry Heneghan asked the Minister for Health whether the reimbursement arrangements under the community drugs schemes will be reviewed to ensure that patients are not financially disadvantaged when unlicensed medicines must be supplied as a result of shortages of licensed products; and if she will make a statement on the matter. [52900/26]
756. Deputy Barry Heneghan asked the Minister for Health whether her Department has assessed the financial impact of medicine shortages on residents of private nursing homes supported under the fair deal scheme, particularly where unlicensed medicines attract additional costs that are not fully covered under existing reimbursement arrangements; and if she will make a statement on the matter. [52901/26]
757. Deputy Barry Heneghan asked the Minister for Health the measures that are being taken by her Department and the HSE to minimise the impact of shortages of essential medicines, including medicines used in the treatment of heart failure and cardiovascular disease, and to ensure continuity of treatment for patients; and if she will make a statement on the matter. [52902/26]
758. Deputy Barry Heneghan asked the Minister for Health whether guidance has been issued to the HSE and community pharmacies regarding the reimbursement of unlicensed medicines supplied in place of licensed medicines that are unavailable due to national shortages; and if she will make a statement on the matter. [52903/26]
759. Deputy Barry Heneghan asked the Minister for Health the number and name of medicines currently subject to national shortages for which pharmacies are routinely sourcing unlicensed alternatives, in tabular form; whether her Department has assessed the additional costs incurred by medical card patients as a consequence; and if she will make a statement on the matter. [52904/26]